Seizures as adverse events of antibiotic drugs : A systematic review

Neurology

Volumn 85, Issue 15, 2015, Pages 1332-1341

  Sutter, Raoul ^a   Rüegg, Stephan ^a   Tschudin Sutter, Sarah ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFIXIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DORIPENEM; ERTAPENEM; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MEROPENEM; PENICILLIN DERIVATIVE; QUINOLONE DERIVATIVE; THEOPHYLLINE; ANTIINFECTIVE AGENT;

ADVERSE DRUG REACTION; DISEASE PREDISPOSITION; DRUG MEGADOSE; ELECTROCONVULSIVE THERAPY; ELECTROENCEPHALOGRAPHY; EVIDENCE BASED PRACTICE; HUMAN; KIDNEY FAILURE; MENTAL DISEASE; PRIORITY JOURNAL; REVIEW; SEIZURE; SYMPTOMATIC EPILEPSY; ANIMAL; CENTRAL NERVOUS SYSTEM; CHEMICALLY INDUCED; DRUG EFFECTS; RISK;

ANIMALS; ANTI-BACTERIAL AGENTS; CENTRAL NERVOUS SYSTEM; CEPHALOSPORINS; HUMANS; IMIPENEM; RISK; SEIZURES;

EID: 84944403052     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000002023     Document Type: Review

References (66)

1. Misra UK, Kalita J, Chandra S, Nair PP. Association of antibiotics with status epilepticus. Neurol Sci 2013; 34: 327-331
2. Loiseau J, Picot MC, Loiseau P. Short-term mortality after a first epileptic seizure: A population-based study. Epilepsia 1999; 40: 1388-1392
3. Sutter R, Marsch S, Fuhr P, Rüegg S. Mortality and recovery from refractory status epilepticus in the ICU: A 7-year observational study. Epilepsia 2013; 54: 502-511
4. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10: 93-102
5. American Academy of Neurology. Clinical Practice Guideline Process Manual, 2011 ed. St. Paul, MN: American Academy of Neurology; 2011
6. Boston Collaborative Drug Surveillance Program. Druginduced convulsions: report from the Boston Collaborative Drug Surveillance Program. Lancet 1972; 2: 677-679
7. Messing RO, Closson RG, Simon RP. Drug-induced seizures: A 10-year experience. Neurology 1984; 34: 1582-1586
8. Van Duijn H, Schwartzkroin PA, Prince DA. Action of penicillin on inhibitory processes in the cat's cortex. Brain Res 1973; 53: 470-476
9. Wong RK, Prince DA. Dendritic mechanisms underlying penicillin-induced epileptiform activity. Science 1979; 204: 1228-1231
10. Weinstein L, Lerner PI, Chew WH. Clinical and bacteriologic studies of the effect of "massive" doses of penicillin G on infections caused by gram-negative bacilli. N Engl J Med 1964; 271: 525-533
11. Saito T, Nakamura M, Watari M, Isse K. Tardive seizure and antibiotics: case reports and review of the literature. J ECT 2008; 24: 275-276
12. Schliamser SE. Neurotoxicity of beta-lactam antibiotics: experimental kinetic and neurophysiological studies. Scand J Infect Dis Suppl 1988; 55: 1-61
13. Sugimoto M, Uchida I, Mashimo T, et al. Evidence for the involvement of GABA(A) receptor blockade in convulsions induced by cephalosporins. Neuropharmacology 2003; 45: 304-314
14. Fernandez-Torre JL, Martinez-Martinez M, Gonzalez-Rato J, et al. Cephalosporin-induced nonconvulsive status epilepticus: clinical and electroencephalographic features. Epilepsia 2005; 46: 1550-1552
15. Choi JY, Seok HY, Lee SH, Kim BJ, Park KW, Jung KY. Epidural adhesiolysis complicated by cefazolin-induced status epilepticus: two cases. Clin Neurol Neurosurg 2008; 110: 1041-1043
16. Bechtel TP, Slaughter RL, Moore TD. Seizures associated with high cerebrospinal fluid concentrations of cefazolin. Am J Hosp Pharm 1980; 37: 271-273
17. Tanaka A, Takechi K, Watanabe S, Tanaka M, Suemaru K, Araki H. Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem. Int J Clin Pharm 2013; 35: 683-687
18. Hocker S, Rabinstein AA. Cefepime neurotoxicity can mimic postanoxic coma with myoclonic status epilepticus. Neurol Clin Pract 2011; 1: 73-75
19. Schmutzhard E, Williams KJ, Vukmirovits G, Chmelik V, Pfausler B, Featherstone A. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults: Meropenem Meningitis Study Group. J Antimicrob Chemother 1995; 36(suppl A): 85-97
20. Fugate JE, Kalimullah EA, Hocker SE, Clark SL, Wijdicks EF, Rabinstein AA. Cefepime neurotoxicity in the intensive care unit: A cause of severe, underappreciated encephalopathy. Crit Care 2013; 17: R264
21. FDA: The United States Food and Drug Administration Drug Safety Communication. Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment [online]. Available at: http://www.fda.gov/Drugs/DrugSafety/ucm309661.htm. Accessed April 29, 2015
22. Garces EO, Andrade De Anzambuja MF, da Silva D, Bragatti JA, Jacoby T, Saldanha Thome F. Renal failure is a risk factor for cefepime-induced encephalopathy. J Nephrol 2008; 21: 526-534
23. Naeije G, Lorent S, Vincent JL, Legros B. Continuous epileptiform discharges in patients treated with cefepime or meropenem. Arch Neurol 2011; 68: 1303-1307
24. Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy 2011; 31: 408-423
25. Norrby SR. Neurotoxicity of carbapenem antibacterials. Drug Saf 1996; 15: 87-90
26. Hori S, Kurioka S, Matsuda M, Shimada J. Inhibitory effect of cephalosporins on gamma-aminobutyric acid receptor binding in rat synaptic membranes. Antimicrob Agents Chemother 1985; 27: 650-651
27. Kamei C, Sunami A, Tasaka K. Epileptogenic activity of cephalosporins in rats and their structure-activity relationship. Epilepsia 1983; 24: 431-439
28. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. Am J Med 1988; 84: 911-918
29. Koppel BS, Hauser WA, Politis C, Van Duin D, Daras M. Seizures in the critically ill: the role of imipenem. Epilepsia 2001; 42: 1590-1593
30. Lane M, Kania D, Rapp RP. Seizures related to use of imipenem-cilastatin. Am J Health Syst Pharm 1996; 53: 1605-1606
31. Pestotnik SL, Classen DC, Evans RS, Stevens LE, Burke JP. Prospective surveillance of imipenem/cilastatin use and associated seizures using a hospital information system. Ann Pharmacother 1993; 27: 497-501
32. Linden P. Safety profile of meropenem: an updated review of over 6, 000 patients treated with meropenem. Drug Saf 2007; 30: 657-668
33. Cunha BA. Meropenem in elderly and renally impaired patients. Int J Antimicrob Agents 1999; 11: 167-177
34. Horiuchi M, Kimura M, Tokumura M, Hasebe N, Arai T, Abe K. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with beta-lactam antibiotics. Toxicology 2006; 222: 114-124
35. Redman R, File TM Jr. Safety of intravenous infusion of doripenem. Clin Infect Dis 2009; 49(suppl 1): S28-S35
36. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis. Antimicrob Agents Chemother 2009; 53: 3782-3792
37. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: A phase III, prospective, multicenter, randomized, doubleblind, noninferiority study. Clin Ther 2008; 30: 868-883
38. Rea-Neto A, Niederman M, Lobo SM, et al. Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: A randomized, open-label, multicenter study. Curr Med Res Opin 2008; 24: 2113-2126
39. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: A multicenter, randomized study. Crit Care Med 2008; 36: 1089-1096
40. Mancl EE, Gidal BE. The effect of carbapenem antibiotics on plasma concentrations of valproic acid. Ann Pharmacother 2009; 43: 2082-2087
41. Green MA, Halliwell RF. Selective antagonism of the GABA(A) receptor by ciprofloxacin and biphenylacetic acid. Br J Pharmacol 1997; 122: 584-590
42. Tsutomi Y, Matsubayashi K, Akahane K. Quantitation of GABAA receptor inhibition required for quinoloneinduced convulsions in mice. J Antimicrob Chemother 1994; 34: 737-746
43. Carranco E, Kareus J, Co S, Peak V, Al-Rajeh S. Carbamazepine toxicity induced by concurrent erythromycin therapy. Arch Neurol 1985; 42: 187-188
44. Keranen T, Jolkkonen J, Jensen PK, Menge GP, Andersson P. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86: 120-123
45. Thomsen MS, Groes L, Agerso H, Kruse T. Lack of pharmacokinetic interaction between tiagabine and erythromycin. J Clin Pharmacol 1998; 38: 1051-1056
46. Uzman S, Uludag Yanaral T, Toptas M, Koc A, Tas A, Bican G. Acute isoniazid intoxication: an uncommon cause of convulsion, coma and acidosis. Tuberk Toraks 2013; 61: 50-53
47. Puri MM, Kumar L, Vishwakarma PD, Behera D. Seizures with single therapeutic dose of isoniazid. Indian J Tuberc 2012; 59: 100-102
48. Topcu I, Yentur EA, Kefi A, Ekici NZ, SakaryaM. Seizures, metabolic acidosis and coma resulting from acute isoniazid intoxication. Anaesth Intensive Care 2005; 33: 518-520
49. Steinmann RA, Rickel MK. A 23-year-old with refractory seizures following an isoniazid overdose. J Emerg Nurs 2002; 28: 7-10
50. Asnis DS, Bhat JG, Melchert AF. Reversible seizures and mental status changes in a dialysis patient on isoniazid preventive therapy. Ann Pharmacother 1993; 27: 444-446
51. Watkins RC, Hambrick EL, Benjamin G, Chavda SN. Isoniazid toxicity presenting as seizures and metabolic acidosis. J Natl Med Assoc 1990; 82: 57, 62, 64
52. Nelson LG. Grand mal seizures following overdose of isoniazid: A report of four cases. Am Rev Respir Dis 1965; 91: 600-604
53. Tibussek D, Mayatepek E, Distelmaier F, Rosenbaum T. Status epilepticus due to attempted suicide with isoniazid. Eur J Pediatr 2006; 165: 136-137
54. Wood JD, Peesker SJ. A correlation between changes in GABA metabolism and isonicotinic acid hydrazideinduced seizures. Brain Res 1972; 45: 489-498
55. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54: 53-58
56. Villikka K, Kivisto KT, Luurila H, Neuvonen PJ. Rifampin reduces plasma concentrations and effects of zolpidem. Clin Pharmacol Ther 1997; 62: 629-634
57. Cholongitas E, Karatzi C, Spyrou S, Georgousaki C, Dasenaki M. Linezolid-induced complex partial seizures in a patient with epilepsy. Scand J Infect Dis 2009; 41: 540-541
58. Shneker BF, Baylin PD, Nakhla ME. Linezolid inducing complex partial status epilepticus in a patient with epilepsy. Neurology 2009; 72: 378-379
59. Spapen HD, Honore PM, Gregoire N, et al. Convulsions and apnoea in a patient infected with New Delhi metallobeta-lactamase-1 Escherichia coli treated with colistin. J Infect 2011; 63: 468-470
60. Commission on Epidemiology and Prognosis of the International League Against Epilepsy. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993; 34: 592-596
61. Anzellotti F, Ricciardi L, Monaco D, et al. Cefiximeinduced nonconvulsive status epilepticus. Neurol Sci 2012; 33: 325-329
62. Coves-Orts FJ, Borras-Blasco J, Navarro-Ruiz A, Murcia-Lopez A, Palacios-Ortega F. Acute seizures due to a probable interaction between valproic acid and meropenem. Ann Pharmacother 2005; 39: 533-537
63. Fudio S, Carcas A, Pinana E, Ortega R. Epileptic seizures caused by low valproic acid levels from an interaction with meropenem. J Clin Pharm Ther 2006; 31: 393-396
64. Lunde JL, Nelson RE, Storandt HF. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. Pharmacotherapy 2007; 27: 1202-1205
65. Liao FF, Huang YB, Chen CY. Decrease in serum valproic acid levels during treatment with ertapenem. Am J Health Syst Pharm 2010; 67: 1260-1264
66. Bird SB, Orr PG, Mazzola JL, Brush DE, Boyer EW. Levofloxacin-related seizure activity in a patient with Alzheimer's disease: assessment of potential risk factors. J Clin Psychopharmacol 2005; 25: 287-288